Header links
Intranet
Donate now
image/svg+xml Map
Contact us

General finder

What are you looking for?

Write the name, title or any keyword related to what you are looking for and select which content category it belongs to.

Year
2024
Data d'inici
Data de tancament
Descripció
Project Manager for Internal Strategy Area_20240170
Codi
2024-170
URL Document vinculat
http://vhir.vallhebron.com//DDGRecerca//OFERTESTREBALL//2024//2024_0170//2024_0170_001.pdf
Reclutant
Inactiu
Year
2024
Data d'inici
Data de tancament
Descripció
Post-Award National Project Manager_20240168
Codi
2024-168
URL Document vinculat
http://vhir.vallhebron.com//DDGRecerca//OFERTESTREBALL//2024//2024_0168//2024_0168_001.pdf
Reclutant
Inactiu
Year
2024
Data d'inici
Data de tancament
Descripció
IT Product Owner_20240167
Codi
2024-167
URL Document vinculat
http://vhir.vallhebron.com//DDGRecerca//OFERTESTREBALL//2024//2024_0167//2024_0167_001.pdf
Reclutant
Inactiu

Professionals

Anna Jeanne Behr

Professionals

Sonia Fuertes Castillo

Professionals

Pedro Alejandro Gil Millán

Professionals

Marc Tort Lacambra

Professionals

Erica Espejo Basilio

Professionals

Eddie Pradas Gracia

Professionals

Jorge Fernandez Engroba

Professionals

Roger Rica Peiro

Professionals

Sara García Hidalgo

Professionals

Tatiana Pablos Jiménez
Year
2024
Data d'inici
Data de tancament
Descripció
Administrative Accountant_20240165
Codi
2024-165
URL Document vinculat
http://vhir.vallhebron.com//DDGRecerca//OFERTESTREBALL//2024//2024_0165//2024_0165_001.pdf
Reclutant
Inactiu
Year
2024
Data d'inici
Data de tancament
Grup de recerca
Childhood Cancer and Blood Disorders
Descripció
Pediatric Oncology Nutritionist_20240166
Codi
2024-166
URL Document vinculat
http://vhir.vallhebron.com//DDGRecerca//OFERTESTREBALL//2024//2024_0166//2024_0166_001.pdf
Reclutant
Inactiu

Estudio de fase 3 multicéntrico, de etiqueta abierta para evaluar la eficacia, farmacocinética, seguridad e inmunogenicidad del ustekinumab administrado porvía subcutánea en participantes pediátricos con artritis psoriásica juvenil activa(PSUMMIT Jr)

Contact
  • Protocol code: CNTO1275JPA3001
  • EudraCT code: 2020-005503-40
  • Principal investigator:  Lopez Corbeto, Mireia
  • Research group:  Reumatologia
  • Service: Reumatologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio multicéntrico y abierto para evaluar la seguridad, la tolerabilidad, la farmacocinética y el efecto sobre las convulsiones y los síntomas conductuales del radiprodil en pacientes con complejo de esclerosis tuberosa (CET) o displasia cortical focal (DCF) tipo II

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A randomised, double-blind, placebo-controlled, parallel group trial evaluating safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 one tablet once daily over 12 weeks versus placebo in adult patients with cystic fibrosis bronchiectasis (ClairaflyTM)

Contact
  • Protocol code: 1397-0013
  • EudraCT code: No aplica
  • Pathology: Malalties del sistema respiratori
  • Principal investigator:  Álvarez Fernandez, Antonio
  • Research group:  Pneumologia
  • Service: Pneumologia
  • Phase: Fase II
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de seguimiento a largo plazo de pacientes con MPS IIIA procedentes de ensayos clínicos de terapia génica que incluyen la administración de ABO-102 (scAAV9.U1a.hSGSH)

Contact
  • Protocol code: LTFU-ABO-102
  • EudraCT code: 2019-002979-34
  • Pathology: Nervous system diseases
  • Principal investigator:  Toro Riera, Mireia del
  • Research group:  Neurologia pediàtrica
  • Service: Pediatria General i Especialitats
  • Phase: Phase III
  • Recruiting: Closed
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A phase 3, multicentre, randomised, double-blind, vehicle-controlled, parallel-group study to evaluate, the efficacy and safety of tribanulib 10 mg, ointment applied to a treatment, field larger than 25 cm and up to 10 cm in adult patients with actinic keratosis.

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.